Array-based comparative genomic hybridization (CGHarray) has a powerful potential for high-throughput identification of genetic aberrations in cell genomes. We identified a homozygous loss of ADAM23 (2q33.3) in the course of a program to screen a panel of gastric cancer (GC) cell lines (1/32, 3.1%) for genomic copy-number aberrations using our custom-made CGH-array. Infrequent homozygous deletion of ADAM23 was also seen in primary gastric tumors (1/39, 2.6%). ADAM23 mRNA was expressed in normal stomach tissue, but not in the majority of GC cell lines without homozygous deletion of this gene. Expression of ADAM23 mRNA was restored to gene-silenced GC cells after treatment with 5-aza 2 0 -deoxycytidine. The methylation status of the ADAM23 CpG island, which showed promoter activity, correlated inversely with its expression. Methylation of this CpG island was observed both in GC cell lines and in primary GC tissues; in primary tumors with a hypermethylated CpG island, expression of ADAM23 was lower than in adjacent noncancerous tissues. Moreover, restoration of ADAM23 in GC cells reduced their numbers in colonyformation assays. These results suggest that genetic or epigenetic silencing by hypermethylation of the ADAM23 CpG-rich promoter region leads to loss of ADAM23 function, which may be a factor in gastric carcinogenesis.
Introduction
Members of the ADAM family of disintegrins and metalloproteinases belong to the zinc protease superfamily. ADAM molecules contain both disintegrin and metalloprotease domains (Seals and Courtneidge, 2003) , and they modulate a variety of cell-cell and cellextracellular matrix interactions. These proteins have been implicated in the control of growth factors and shedding of cytokines, in membrane adhesion, and in cell migration, as well as in processes such as muscle development, fertilization, and determination of cell fates. Any of these activities can be involved in tumorigenesis (Seals and Courtneidge, 2003) . Owing to their multiple functions, some members of the ADAM family have been suspected of involvement in the pathogenesis of breast cancer (O'Shea et al., 2003) , prostate cancer (McCulloch et al., 2004) , non-small-cell lung cancer (Shintani et al., 2004) , and glioblastoma (Kodama et al., 2004) , as well as gastric cancer (GC) (Carl-McGrath et al., 2005) . However, the association between ADAM proteins and gastric carcinogenesis remains unclear. Although most of these molecules are thought to be capable of accelerating tumorigenesis through overexpression, a few of them, including ADAM11 and ADAM23, might be associated with tumorigenesis through their inactivation (Wu et al., 1997; Costa et al., 2004) .
As an alternative to genetic defects that may contribute to human cancers, epigenetic mechanisms that involve DNA methylation and alteration of chromatin structure are important ways to silence many genes transcriptionally, especially tumor suppressor genes. In some breast tumors, the ADAM23 gene has been silenced through DNA methylation (Costa et al., 2004) . However, no one has yet assessed the promoter activity and methylation status of the CpG island around the ADAM23 gene or other mechanisms of gene silencing such as homozygous deletion, nor evaluated potential tumor suppressor activity of the gene product.
In the study reported here, we identified a homozygous loss of ADAM23 (2q33.3) by screening a panel of GC cell lines for copy-number aberrations using arraybased comparative genomic hybridization (CGH-array) analysis relied on a custom-made bacterial artificial chromosome (BAC)-based array. We observed homozygous deletion of ADAM23 in primary GC, albeit infrequently, as well. However, expression of this gene was also lost in the majority of GC cell lines without homozygous loss, although it was present in normal stomach. Those results suggested that when ADAM23 is inactivated epigenetically or genetically, it may be involved in gastric carcinogenesis. To evaluate that hypothesis, we examined the role of DNA methylation within the upstream CpG island in regard to expression of ADAM23 in GC, and tested the effect of restored ADAM23 on the growth of GC cells.
Results

CGH-array analysis of GC cell lines
Copy-number gains and losses were seen to some degree in all of the 32 GC cell lines examined. Since the most common genetic aberrations had already been identified in GC cell lines and primary tumors, we paid attention to more remarkable patterns of chromosomal abnormalities, such as high-level amplifications and homozygous deletions, which are likely to be landmarks of oncogenes and tumor suppressor genes, respectively. Tables 1 and 2 summarize the clones showing high-level amplifications (log2ratio >2.0) or homozygous deletions (log2ratio oÀ2.0), respectively. High-level amplifications were detected in 18 of the 32 GC cell lines, and 16 loci were represented (Table 1) . Among them, loci containing genes that had been reported already as putative oncogenes were detected in more than two cell lines each: MYC, PVT1 (six cell lines), KSAM (four lines), KRAS (three lines), and MET (two lines).
In all, 13 loci were identified as candidate regions for homozygous deletions among 14 of the 32 GC cell lines (Table 2 ). The region containing CDKN2A/p16 (six lines) was the most frequently deleted, and regions that harbored TEK (three lines) and WWOX (two lines; left panel in Figure 1a ) were observed in at least two cell lines each. Genomic polymerase chain reaction (PCR) analysis (Figure 1b ) also confirmed complete losses of candidate genes that located within or around BACs that had been detected as homozygous deletions by analysis on the CGH-array. Among them, homozygous loss at 2q33.3, the location of ADAM23 (right panel in Figures 1a, b , and 2a), had never been documented in GC before, prompting us to examine whether a tumor suppressor gene(s) involved in gastric tumorigenesis might lie within this region.
Identification of gene(s) involved in the homozygous deletion at 2q33.3
To identify all potential target genes for the homozygous deletion at 2q33.3 in HSC43 cells, we first tried to define the region by fluorescence in situ hybridization (FISH), using five BACs as region-specific probes (Figure 2b, c) . No red signals specific for RP11-225L15, which is spotted on the MCG whole genome array-4500, or for RP11-698O13 or RP11-655B6, were detected; however two other BACs, RP11-90D19 and RP11-17I6, showed four green signals each on isochromosomes in HSC43 cells (Figure 2b ). The extent of the homozygous deletion estimated from these observations was approximately 1.5 Mb, and information archived by human genome databases (http://www.ncbi.nlm.nih.gov/ and http:// genome.ucsc.edu/) indicated that five genes are located in the defined region (Figure 2c ). Homozygous deletion of ADAM23, MDH1B, and KIAA0971 (gray arrows in Figure 2c ) was detected only in HSC43 (1/32, 3.1%; Figure 2d ), whereas GPR1 and CPO (black arrows in Figure 2c ) were retained (data not shown).
Loss of ADAM23 expression in GC cell lines
Next we determined expression levels of ADAM23, MDH1B, and KIAA0971 by means of reverse transcriptase (RT)-PCR in all 32 GC cell lines and in normal stomach. The HSC43 cell line as well as 13 lines without homozygous loss within 2q33.3 (41.9%) completely lacked expression of ADAM23 mRNA; eight other lines (25.8%) showed reduced expression compared with normal stomach (Figure 2e ). ADAM23 was more or less expressed in various other tissues including stomach (Figure 2e ). On the other hand, the RT-PCR product of MDH1B was absent less frequently, and that of KIAA0971 was not decreased at all.
Homozygous deletion of ADAM23 in LCM-treated primary tumors
To confirm that homozygous loss of ADAM23 was not an artefact that arose during establishment of the cell lines, we performed genomic PCR using laser-capture microdissection (LCM)-treated primary gastric tumors, and detected homozygous deletion of ADAM23 in one of the 39 tumors examined (2.6%, Figure 2f ).
Effect of demethylation by 5-aza 2 0 -deoxycytidine on ADAM23 expression Aberrant methylation of DNA in 5 0 regulatory regions harboring a higher than expected number of CpG dinucleotides is a key mechanism by which genes relevant to cancer initiation and progression can be silenced (Baylin et al., 1998) . To investigate whether demethylation could restore expression of ADAM23 mRNA, we treated GC cells lacking ADAM23 expression (SNU601 and SH101P4) with 10 mM of 5-aza 2 0 -deoxycytidine (5-aza-dCyd), a methyltransferase inhibitor, for 5 days. ADAM23 mRNA was induced in both cell lines after treatment with 5-aza-dCyd ADAM23 as a potential tumor suppressor for gastric cancer H Takada et al ( Figure 3a ). In addition, we observed elevated expression of mRNA in SNU601 cells after treatment with trichostatin A (TSA), a histone deacetylase inhibitor, alone, and enhancement of expression by 5-aza-dCyd given along with TSA, although treatment with TSA alone had no affect on expression of ADAM23 in SH101P4 cells, indicating that histone deacetylation does play some role in transcriptional silencing of ADAM23 among methylated GC cells.
Promoter activity of the ADAM23 CpG islands
Hypermethylation in CpG-rich promoter or exonic regions is strongly associated with transcriptional silencing of tumor suppressor genes. A 1067-bp sequence (Region II in Figure 3b ) that included exon 1 (À278 to IVS þ 352) of ADAM23 was identified as a CpG island by means of the genome database (http:// www.ebi.ac.uk/emboss/cpgplot/). Others have reported frequent hypermethylation in part of a slightly CpG-rich region approximately 0.5 Mb upstream from the transcription start site (479-bp sequence containing 22 CpG sites, Region I in Figure 3b ) in breast tumors (Costa et al., 2004) . However, no potential association between the degree of methylation of the CpG island located around exon 1 with expression of ADAM23 mRNA has been investigated, nor has the structure of the gene's promoter region or its methylation status in cells lacking ADAM23 expression. Therefore, we tested the promoter activity of the CpG-rich region (Region I) using one 480-bp fragment (Fragment 1) and the CpG island (Region II) using three 1026-, 348-and 677-bp fragments around exon 1 (À341 to þ 685, À341 to þ 7, and þ 9 to þ 685, respectively; Fragments 2-4) in SH101P4 and AZ-521 cells ( Figure 3b ). A remarkable increase in transcriptional activity was observed in constructs containing Fragment 3 (7.4-and 12.7-fold increases, respectively, in SH101P4 and AZ-521 cells), whereas constructs containing Fragment 1, representing the 479-bp region I analysed by Costa et al. (2004) , showed some but much lower transcriptional activity (3.3-and 3.9-fold increases) regardless of the expression status for ADAM23 (Figure 3c ). Therefore, the region around Fragment 3 seems to be the most important sequence for promoting expression of ADAM23.
Methylation status of the ADAM23 CpG island in GC cell lines and primary tumors
To explore the potential role of methylation of CpG islands in silencing the transcription of ADAM23, we first assessed the methylation status of the CpG island in GC-derived cell lines with or without expression of this gene, by means of bisulfite-PCR experiments using appropriate restriction enzymes for each of the four PCR fragments (Regions 1, 2-A, 2-B, and 2-C in Figure 3d ). GC cells lacking ADAM23 expression but without homozygous deletion of this gene (KATO-III, SNU601, and SH101P4) were found to be aberrantly hypermethylated in all regions, although the degree of hypermethylation varied among CpG sites. On the other hand, hypomethylation was seen in ADAM23-expressing GC cells (AZ-521, SNU484, RERF-GC-1B, and NUGC-2). Notably, the NUGC-2 cell line, which expresses ADAM23, was relatively hypermethylated in Region 1 (Figure 3d) ; this implied that Region 2, especially Region 2-A, rather than Region 1, is a more critical site for epigenetic events affecting ADAM23 expression.
We assessed the methylation status of each CpG dinucleotide within the ADAM23 CpG island (Region II) in more detail by bisulfite-sequencing. CpG sites on the CpG island tended to be extensively methylated in ADAM23-nonexpressing cells without homozygous deletions (SNU601, SH101P4), whereas almost all CpG Figure 3e ). Since hypermethylation around Region 2-A (Figure 3b ) would likely be associated with silencing of ADAM23 expression in GCs, we performed methylation-specific PCR (MSP) with primer sets targeted for the most frequently methylated sequence (Figure 3b , e) in primary GCs as well as the rest of our GC cell lines without homozygous loss of ADAM23.
Two representative cell lines without ADAM23 expression were mostly methylated, whereas one ADAM23-expressing cell line was unmethylated, as expected (Figure 4a ). Target sequence was methylated in 19 (61.3%) of the 31 GC cell lines (data not shown). Moreover, we detected its methylation in seven of 16 primary GC tissues (43.8%); four of those seven samples were not methylated in the corresponding noncancerous stomach tissues (Figure 4a ). RT-PCR using these fourpaired samples demonstrated that ADAM23 expression was nevertheless lower in tumor tissues compared with the noncancerous tissues (Figure 4b) . To confirm the results of MSP analysis quantitatively, we performed bisulfite-sequencing of Region 2-A in individual alleles from representative GC samples and their corresponding noncancerous tissues. Aberrant hypermethylation of Region 2-A was detected at frequencies of 20-50% in GC tissues (cases 11, 26, 30 and 35) , which showed a decreased ADAM23 expression compared with the corresponding noncancerous tissue, while no GCs (cases 8 and 13) without reduction of ADAM23 mRNA were methylated (Figure 4c ). Although hypomethylated alleles were also present due to normal tissue components contaminating the tumors, corresponding noncancerous tissues showed hypomethylation of this region (Figure 4c ). These findings indicate that methylation of ADAM23 Region 2-A did not arise during passage of GC cell lines in vitro, but rather may be a true cancer-related event during the pathogenesis of GC.
Suppression of cell growth after restoration of ADAM23 expression
To gain further insight into the potential role of ADAM23 protein in gastric carcinogenesis, we investigated whether restoration of ADAM23 expression would suppress growth of GC cells in which the gene had been silenced. We performed colony-formation assays using the full coding sequence of ADAM23 cloned into a mammalian expression vector. As shown in Figure 4d , 3 weeks after transfection and subsequent selection of drug-resistant colonies, the numbers of large colonies produced by ADAM23-transfected SH101P4 cells decreased compared to cells containing empty vector.
Discussion
CGH-array technology allows high-throughput and quantitative analysis of copy-number changes at high resolution throughout the genome and provides many advantages over conventional CGH and other methods for reliably detecting and precisely mapping chromosomal changes (Snijders et al. , 2001; Inazawa et al., 2004) . In the study reported here, we used our MCG Whole Genome Array-4500, covering the entire human genome with a total of 4523 BACs, to examine 32 GC cell lines for copy-number alterations within smaller regions. Since the most common chromosomal imbalances had already been identified in GC, we focused on the more extreme aberrations, that is, local high-level amplifications and homozygous deletions.
The results of the new CGH-array analysis were mostly in accord with our previous CGH/CGH-array data (Fukuda et al., 2000; Takada et al., 2005) and with other published CGH/CGH-array data derived from analysis of primary gastric tumors (Sakakura et al., 1999; Tay et al., 2003; Kimura et al., 2004; Weiss et al., 2004; Gorringe et al., 2005) . That is, loci that were frequently detected as high-level amplifications in our study contained the same genes whose amplifications had been known to play important roles in pathogenesis of GC as putative oncogenes, such as MYC, PVT1, KSAM, MET, and KRAS (Tahara, 1995; Koo et al., 2000; Peng et al., 2003) . On the other hand, homozygous losses were more frequently identified by MCG Whole Genome Array-4500 than by MCG Cancer Array-800 (b) Images from genomic PCR experiments showing GAPDH, the functional control, and representative genes that were absent in at least one cell line for all cases examined. PLC, normal peripheral lymphocytes ADAM23 as a potential tumor suppressor for gastric cancer H Takada et al (Takada et al., 2005) , probably because homozygous deletions are expected to be quite small and a higherdensity array may be necessary to fully reveal them.
Loci with homozygous losses can flag regions likely to harbor tumor suppressor genes; in fact, some of the loci we detected in our GC cell lines contained representative tumor suppressor genes such as FHIT, CDKN2A/p16, RB1 and WWOX, which had been reported already in connection with various tumors including GC (Akama et al., 1996; Huiping et al., 2002; Feakins et al., 2003; Aqeilan et al., 2004) . We chose to focus on the complete loss at 2q33.3 observed in one of the cell lines, because (a) this locus was hemizygously deleted in five of the other 31 lines (15.6%, data not shown) but it was not previously known to harbor any tumor suppressor genes involved in the pathogenesis of GC, and (b) this region contained one potential candidate, ADAM23, whose epigenetic silencing through DNA methylation had been reported in breast tumors (Costa et al., 2004) . Indeed, RT-PCR analysis of genes within this region identified ADAM23 as the most probable target, because expression of this gene was frequently silenced in our panel of GC cell lines, whereas it was expressed in normal stomach and other tissues, even though its expression level was various among tissues. Since genomic PCR experiments demonstrated infrequent homozygous deletion of ADAM23 in primary gastric tumors as well, this gene is likely to be inactivated mainly by epigenetic mechanisms such as DNA methylation. Costa et al. (2004) reported that methylation in a region located approximately 0.5 kb upstream from the transcription initiation site of the ADAM23 gene was ADAM23 as a potential tumor suppressor for gastric cancer H Takada et al strongly associated with its altered expression in breast tumor cell lines. However, a site that fulfills the accepted criteria for CpG islands exists in another area of the ADAM23 gene, and little was known about that sequence. In the present study, we demonstrated that (a) an actual CpG island upstream of the transcriptional start site of the ADAM23 gene is the most important sequence for promoting expression of this gene; (b) the methylation status around that fragment seems to be inversely correlated with expression of the gene; and (c) hypermethylation of this region, along with decreased gene expression, occurs in primary gastric tumors compared with noncancerous gastric tissue. These factors indicated that aberrant hypermethylation within a CpG island having promoter activity is likely to be one of the important mechanisms leading to inactivation of the ADAM23 gene in gastric neoplasm. According to analysis of primary samples, hypermethylation of ADAM23 CpG island with reduced expression of this gene seems to occur in a tumorspecific manner; nevertheless, some cases showed its methylation both in tumors and in the corresponding noncancerous tissues (data not shown). Since methylation of several genes appears to follow a chronological order during carcinogenesis in stomach tissue (Kang et al., 2003) , transcriptional silencing of tumor-related genes, including ADAM23, by aberrant methylation of CpG islands is likely to be established during an early stage in the multistep process of gastric carcinogenesis.
The exact roles of ADAM proteins, including ADAM23, in carcinogenesis remain largely unknown. Our colony-formation assays using ADAM23-transfected GC cells revealed growth-suppressing and/or antiproliferative activity of the ADAM23 protein; neither had ever been demonstrated before. So far, little information is available about the functional consequences of ADAM23 loss in terms of carcinogenesis; however, the unique structure of ADAM molecules allows us to postulate an ability of ADAM23 to function as an adhesion molecule. The disintegrin-like domain of ADAM23 promotes attachment of human cells of neural origin, such as neuroblastoma or astrocytoma cells (Cal et al., 2000) . Therefore loss of ADAM23, which is likely to play an important role with regard to cell-cell and cell-extracellular matrix interactions in gastric tissue as well, might be essential for the progression of GC. Additional studies can be designed to unravel the carcinogenic consequences of loss of ADAM23 function in gastric tissue.
Materials and methods
Cell lines and primary tumors
A total of 32 GC cell lines were employed. Features of those cell lines except Takigawa were described in the previous reports (Fukuda et al., 2000; Takada et al., 2005) . All cell lines were maintained in RPMI-1640 supplemented with 10% fetal bovine serum and 100 units/ml penicillin/100 mg/ml streptomycin. Primary tumor samples were obtained from 55 patients who were undergoing surgery at the National Defense Medical College in Saitama or the National Cancer Center Hospital in Tokyo, Japan, with prior written consent from each patient in the formal style and after approval by the local ethics committees. Samples from 39 patients with well-differentiated adenocarcinomas were paraffin-embedded for LCM after 24 h methanol fixation, as described elsewhere (Noguchi et al., 1997) . From the other 16 patients we obtained paired samples from cancerous and adjacent noncancerous tissues, which were frozen immediately in liquid nitrogen and stored at À801C until required. None of the patients had been administered preoperative radiation, chemotherapy, or immunotherapy.
CGH-array analysis
Hybridizations were carried out as described elsewhere (Sonoda et al., 2004) with minor modifications. Briefly, test and reference DNAs were labeled, respectively, with Cy3-and Cy5-dCTP, precipitated together with ethanol in the presence of Cot-1 DNA, redissolved in a hybridization mixture (50% formamide, 10% dextran sulfate, 2 Â standard saline citrate (SSC), 4% sodium dodecyl sulfate (SDS), pH 7), and denatured at 751C for 10 min. After a 40-min preincubation at 421C, each mixture was applied to array slides and incubated at 501C for 10 min, 461C for 10 min, and 431C for 60 h in a hybridization machine (GeneTAC; Harvard Bioscience, Holliston, MA, USA). Hybridized slides were washed once in a solution of 50% formamide, 2x SSC (pH 7.0) for 10 min at 501C and in 1 Â SSC for 10 min at 421C, then scanned with a GenePix 4000B (Axon Instruments, Foster City, CA, USA). Acquired images were analysed with GenePix Pro 4.1 imaging software (Axon Instruments). Fluorescence ratios were normalized so that the mean of the middle third of log2ratios across the array was zero. Average ratios that deviated significantly (>2 s.d.) from zero were considered abnormal.
Fluorescence in situ hybridization
Metaphase chromosomes were prepared from normal male lymphocytes and from each GC cell line. FISH analyses were performed as described previously (Fukuda et al., 2000) , using BACs located around the region of interest as probes.
Screening of primary tumors for homozygous deletions by genomic PCR
Methanol-fixed, paraffin-embedded tissues were prepared for LCM with a PixCell II LCM system (Arcturus Engineering, Mountain View, CA, USA). Each genomic DNA was isolated in lysis buffer (10 mM Tris-HCl at pH 7.5, 1 mM EDTA, 0.5% SDS) and amplified by adaptor-ligation-mediated PCR after end-filling, as described by Tanabe et al. (2003) .
We screened DNAs from 39 primary GCs for homozygous losses by genomic PCR. All the relevant primer sequences are available on request.
Reverse transcriptase-polymerase chain reaction
Single-stranded cDNAs were generated from total RNAs using the SuperScriptt First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA), and amplified with primers specific for each gene. The gene encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified at the same time to estimate the efficiency of cDNA synthesis.
Drug treatment
Cells were treated with 10 mM of 5-aza-dCyd for 5 days and/or with 10 ng/ml TSA for varying periods. For the synergistic study, 10 mM of 5-aza-dCyd was present in the cultures for 5 days, and 10 ng/ml TSA was added for the last 24 h.
Promoter reporter assay
We obtained by PCR three DNA fragments (1026-, 348-and 677-bp, Fragments 2-4) around the CpG island of ADAM23 predicted by the CpGPLOT program (http://www.ebi. ac.uk/ emboss/cpgplot/) and a 480-bp slightly CpG-rich region (Fragment 1) upstream from exon 1 of ADAM23 as a target for DNA methylation (Figure 3b ). Each fragment was ligated into the pGL3-Basic vector (Promega, Madison, WI, USA), and an equal amount of each construct was introduced into cells along with an internal control vector (pRL-hTK, Promega), using FuGENE 6 (Roche Diagnostics, Tokyo, Japan). A pGL3-Basic vector without insert served as a negative control. Firefly luciferase and Renilla luciferase activities were each measured 36 h after transfection, using the Dual-Luciferase Reporter Assay System (Promega); relative luciferase activities were calculated and normalized versus Renilla luciferase activity.
Bisulfite-PCR analysis and bisulfite-sequencing
Genomic DNAs were treated with sodium bisulfite using an EZ DNA Methylation kit (Zymo Research, Orange, CA, USA), and subjected to PCR using primer sets designed to amplify the regions of interest. To analyse the CpG island (Region II in Figure 3b ), that sequence was divided into three PCR fragments (Regions 2-A, 2-B, and 2-C in Figure 3b ).
For bisulfite-PCR analysis, PCR products were digested with HhaI or BstUI, which recognizes sequences unique to the methylated alleles but cannot recognize unmethylated alleles, and electrophoresed. For bisulfite-sequencing, the PCR products were subcloned and then sequenced.
Methylation-specific PCR
Genomic DNA treated with sodium bisulfite was amplified using primers specific to the methylated and unmethylated forms of DNA sequences of interest. DNAs from cell line AZ-521 and from peripheral blood lymphocytes of a healthy male, which were recognized as unmethylated forms by bisulfitesequencing analysis, were used as negative controls for MSP assay; DNAs from cell lines SNU601 and SH101P4, recognized as methylated, served as positive controls for methylated alleles. PCR products were visualized on 3% agarose gels stained with ethidium bromide.
Transient transfection, Western blotting, and colony-formation assays
A plasmid expressing a Myc-tagged ADAM23 (pCMV-Tag3-ADAM23) was obtained by cloning the full coding sequence of ADAM23 into the pCMV-Tag3 vector (Stratagene, La Jolla, CA, USA) in-frame, along with the Myc-epitope. pCMVTag3-ADAM23, or the empty vector (pCMV-Tag3-mock) control, were transfected into cells for colony-formation assays as described elsewhere (Imoto et al., 2003) . Expression of ADAM23 protein in transiently transfected cells was confirmed 48 h after transfection by Western blot analysis using anti-Myc antibody (Cell Signaling Technology, Beverly, MA, USA), as described elsewhere (Yuki et al., 2004) . After 3 weeks of incubation with appropriate concentrations of G418 in six-well plates, cells were fixed with 70% ethanol and stained with crystal violet.
